Standard BioTools Inc. (LAB) stock
LABNasdaqPharmaceutical PreparationsFiscal year ends December 31
Financials through Q2 FY2026, quarter ended Jun 30, 2026Last filing: 10-Q on Nov 3, 2026Score 12/3085% below fair value
$0.71+0.06 (+8.60%)
Close on Nov 13, 2026Market cap $277.71MP/E 3.2Yield –
Standard BioTools operating cash flow
Operating cash flow is the cash the business generates from its day-to-day operations.
Standard BioTools's operating cash flow for the twelve months ending Jun 30, 2026 was -$80.30M. For fiscal 2025 it was -$74.34M. The highest annual figure on record is -$1.59M in fiscal 2013.
Annual operating cash flow
| Period | Period end | Value | Change |
|---|---|---|---|
| FY2025 | Dec 31, 2025 | -$74.34M | – |
| FY2024 | Dec 31, 2024 | -$143.45M | – |
| FY2023 | Dec 31, 2023 | -$43.29M | – |
| FY2022 | Dec 31, 2022 | -$89.37M | – |
| FY2021 | Dec 31, 2021 | -$44.06M | – |
| FY2020 | Dec 31, 2020 | -$15.42M | – |
| FY2019 | Dec 31, 2019 | -$35.21M | – |
| FY2018 | Dec 31, 2018 | -$25.20M | – |
| FY2017 | Dec 31, 2017 | -$24.10M | – |
| FY2016 | Dec 31, 2016 | -$39.14M | – |
| FY2015 | Dec 31, 2015 | -$34.73M | – |
| FY2014 | Dec 31, 2014 | -$22.62M | – |
| FY2013 | Dec 31, 2013 | -$1.59M | – |
| FY2012 | Dec 31, 2012 | -$17.48M | – |
| FY2011 | Dec 31, 2011 | -$17.54M | – |
| FY2010 | Dec 31, 2010 | -$11.51M | – |
| FY2009 | Dec 31, 2009 | -$19.51M | – |
Quarterly operating cash flow
Change is against the same quarter a year earlier.
| Period | Period end | Value | Change |
|---|---|---|---|
| Q2 FY2026 | Jun 30, 2026 | -$10.31M | – |
| Q1 FY2026 | Mar 31, 2026 | -$46.60M | – |
| Q4 FY2025 | Dec 31, 2025 | -$1.19M | – |
| Q3 FY2025 | Sep 30, 2025 | -$22.20M | – |
| Q2 FY2025 | Jun 30, 2025 | -$20.67M | – |
| Q1 FY2025 | Mar 31, 2025 | -$30.28M | – |
| Q4 FY2024 | Dec 31, 2024 | -$14.06M | – |
| Q3 FY2024 | Sep 30, 2024 | -$27.87M | – |
| Q2 FY2024 | Jun 30, 2024 | -$39.05M | – |
| Q1 FY2024 | Mar 31, 2024 | -$62.48M | – |
| Q4 FY2023 | Dec 31, 2023 | -$14.06M | – |
| Q3 FY2023 | Sep 30, 2023 | -$11.41M | – |
| Q2 FY2023 | Jun 30, 2023 | -$9.33M | – |
| Q1 FY2023 | Mar 31, 2023 | -$8.49M | – |
| Q4 FY2022 | Dec 31, 2022 | -$19.18M | – |
| Q3 FY2022 | Sep 30, 2022 | -$24.61M | – |
| Q2 FY2022 | Jun 30, 2022 | -$29.99M | – |
| Q1 FY2022 | Mar 31, 2022 | -$15.59M | – |
| Q4 FY2021 | Dec 31, 2021 | -$7.00M | – |
| Q3 FY2021 | Sep 30, 2021 | -$9.49M | – |
| Q2 FY2021 | Jun 30, 2021 | -$14.66M | – |
| Q1 FY2021 | Mar 31, 2021 | -$12.90M | – |
| Q4 FY2020 | Dec 31, 2020 | -$3.73M | – |
| Q3 FY2020 | Sep 30, 2020 | -$4.60M | – |
| Q2 FY2020 | Jun 30, 2020 | -$2.79M | – |
| Q1 FY2020 | Mar 31, 2020 | -$4.30M | – |
| Q4 FY2019 | Dec 31, 2019 | -$5.52M | – |
| Q3 FY2019 | Sep 30, 2019 | -$4.55M | – |
| Q2 FY2019 | Jun 30, 2019 | -$5.01M | – |
| Q1 FY2019 | Mar 31, 2019 | -$20.13M | – |
| Q4 FY2018 | Dec 31, 2018 | -$638.00K | -196.5% |
| Q3 FY2018 | Sep 30, 2018 | -$4.06M | – |
| Q2 FY2018 | Jun 30, 2018 | -$4.32M | – |
| Q1 FY2018 | Mar 31, 2018 | -$16.18M | – |
| Q4 FY2017 | Dec 31, 2017 | $661.00K | – |
| Q3 FY2017 | Sep 30, 2017 | -$7.98M | – |
| Q2 FY2017 | Jun 30, 2017 | -$8.29M | – |
| Q1 FY2017 | Mar 31, 2017 | -$8.49M | – |
| Q4 FY2016 | Dec 31, 2016 | -$10.73M | – |
| Q3 FY2016 | Sep 30, 2016 | -$13.26M | – |
See a number that looks wrong?